Table of Contents

1 RESEARCH SCOPE

• 1.1 Research Product Definition
• 1.2 Research Segmentation
  • 1.2.1 Product Type
  • 1.2.2 Main product Type of Major Players
• 1.3 Demand Overview
• 1.4 Research Methodology

2 GLOBAL SECONDARY HYPERPARATHYROIDISM DRUG INDUSTRY

• 2.1 Summary about Secondary Hyperparathyroidism Drug Industry
• 2.2 Secondary Hyperparathyroidism Drug Market Trends
  • 2.2.1 Secondary Hyperparathyroidism Drug Production & Consumption Trends
  • 2.2.2 Secondary Hyperparathyroidism Drug Demand Structure Trends
• 2.3 Secondary Hyperparathyroidism Drug Cost & Price

3 MARKET DYNAMICS

• 3.1 Manufacturing & Purchasing Behavior in 2020
• 3.2 Market Development under the Impact of COVID-19
  • 3.2.1 Drivers
  • 3.2.2 Restraints
  • 3.2.3 Opportunity
  • 3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

• 4.1 Region Segmentation (2017 to 2021f)
  • 4.1.1 North America (U.S., Canada and Mexico)
  • 4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
  • 4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
  • 4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
  • 4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
• 4.2 Product Type Segmentation (2017 to 2021f)
  • 4.2.1 Evocalcet
  • 4.2.2 LNP-1892
  • 4.2.3 AJT-240
  • 4.2.4 Cinacalcet Hydrochloride
  • 4.2.5 CTA-091
  • 4.2.6 Others
• 4.3 Consumption Segmentation (2017 to 2021f)
  • 4.3.1 Hospital
  • 4.3.2 Clinic
  • 4.3.3 Others

5 NORTH AMERICA MARKET SEGMENT

• 5.1 Region Segmentation (2017 to 2021f)
  • 5.1.1 U.S.
  • 5.1.2 Canada
  • 5.1.3 Mexico
• 5.2 Product Type Segmentation (2017 to 2021f)
  • 5.2.1 Evocalcet
  • 5.2.2 LNP-1892
  • 5.2.3 AJT-240
  • 5.2.4 Cinacalcet Hydrochloride
  • 5.2.5 CTA-091
  • 5.2.6 Others
• 5.3 Consumption Segmentation (2017 to 2021f)
  • 5.3.1 Hospital
  • 5.3.2 Clinic
  • 5.3.3 Others
• 5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

• 6.1 Region Segmentation (2017 to 2021f)
  • 6.1.1 Germany
  • 6.1.2 UK
  • 6.1.3 France
  • 6.1.4 Italy
  • 6.1.5 Rest of Europe
• 6.2 Product Type Segmentation (2017 to 2021f)
  • 6.2.1 Evocalcet
  • 6.2.2 LNP-1892
  • 6.2.3 AJT-240
  • 6.2.4 Cinacalcet Hydrochloride
  • 6.2.5 CTA-091
  • 6.2.6 Others
• 6.3 Consumption Segmentation (2017 to 2021f)
  • 6.3.1 Hospital
  • 6.3.2 Clinic
  • 6.3.3 Others
• 6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

• 7.1 Region Segmentation (2017 to 2021f)
  • 7.1.1 China
  • 7.1.2 India
  • 7.1.3 Japan
  • 7.1.4 South Korea
  • 7.1.5 Southeast Asia
  • 7.1.6 Australia
  • 7.1.7 Rest of Asia Pacific
• 7.2 Product Type Segmentation (2017 to 2021f)
  • 7.2.1 Evocalcet
  • 7.2.2 LNP-1892
  • 7.2.3 AJT-240
  • 7.2.4 Cinacalcet Hydrochloride
  • 7.2.5 CTA-091
  • 7.2.6 Others
• 7.3 Consumption Segmentation (2017 to 2021f)
  • 7.3.1 Hospital
  • 7.3.2 Clinic
  • 7.3.3 Others
• 7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

• 8.1 Region Segmentation (2017 to 2021f)
  • 8.1.1 Brazil
  • 8.1.2 Argentina
  • 8.1.3 Rest of Latin America
• 8.2 Product Type Segmentation (2017 to 2021f)
  • 8.2.1 Evocalcet
  • 8.2.2 LNP-1892
  • 8.2.3 AJT-240
  • 8.2.4 Cinacalcet Hydrochloride
  • 8.2.5 CTA-091
  • 8.2.6 Others
• 8.3 Consumption Segmentation (2017 to 2021f)
  • 8.3.1 Hospital
  • 8.3.2 Clinic
  • 8.3.3 Others
• 8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

• 9.1 Region Segmentation (2017 to 2021f)
  • 9.1.1 GCC
  • 9.1.2 North Africa
  • 9.1.3 South Africa
  • 9.1.4 Rest of Middle East and Africa
• 9.2 Product Type Segmentation (2017 to 2021f)
  • 9.2.1 Evocalcet
  • 9.2.2 LNP-1892
  • 9.2.3 AJT-240
  • 9.2.4 Cinacalcet Hydrochloride
  • 9.2.5 CTA-091
  • 9.2.6 Others
• 9.3 Consumption Segmentation (2017 to 2021f)
  • 9.3.1 Hospital
  • 9.3.2 Clinic
  • 9.3.3 Others
• 9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

• 10.1 Brief Introduction of Major Players
  • 10.1.1 Deltanoid Pharmaceuticals Inc
  • 10.1.2 EA Pharma Co Ltd
  • 10.1.3 Lupin Ltd
  • 10.1.4 Mitsubishi Tanabe Pharma Corp
  • 10.1.5 OPKO Health Inc
  • 10.1.6 Shire Plc
• 10.2 Secondary Hyperparathyroidism Drug Sales Date of Major Players (2017-2020e)
  • 10.2.1 Deltanoid Pharmaceuticals Inc
  • 10.2.2 EA Pharma Co Ltd
  • 10.2.3 Lupin Ltd
  • 10.2.4 Mitsubishi Tanabe Pharma Corp
  • 10.2.5 OPKO Health Inc
  • 10.2.6 Shire Plc
• 10.3 Market Distribution of Major Players
• 10.4 Global Competition Segmentation

11 MARKET FORECAST

• 11.1 Forecast by Region
• 11.2 Forecast by Demand
• 11.3 Environment Forecast
  • 11.3.1 Impact of COVID-19
  • 11.3.2 Geopolitics Overview
  • 11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

List of Table

1.Table Secondary Hyperparathyroidism Drug Product Type Overview

2.Table Secondary Hyperparathyroidism Drug Product Type Market Share List

3.Table Secondary Hyperparathyroidism Drug Product Type of Major Players

4.Table Brief Introduction of Deltanoid Pharmaceuticals Inc

5.Table Brief Introduction of EA Pharma Co Ltd

6.Table Brief Introduction of Lupin Ltd

7.Table Brief Introduction of Mitsubishi Tanabe Pharma Corp

8.Table Brief Introduction of OPKO Health Inc

9.Table Brief Introduction of Shire Plc

10.Table Products & Services of Deltanoid Pharmaceuticals Inc

11.Table Products & Services of EA Pharma Co Ltd

12.Table Products & Services of Lupin Ltd

13.Table Products & Services of Mitsubishi Tanabe Pharma Corp

14.Table Products & Services of OPKO Health Inc

15.Table Products & Services of Shire Plc

16.Table Market Distribution of Major Players

17.Table Global Major Players Sales Revenue (Million USD) 2017-2020e

18.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

19.Table Global Secondary Hyperparathyroidism Drug Market Forecast (Million USD) by Region 2021f-2026f

20.Table Global Secondary Hyperparathyroidism Drug Market Forecast (Million USD) Share by Region 2021f-2026f

21.Table Global Secondary Hyperparathyroidism Drug Market Forecast (Million USD) by Demand 2021f-2026f

22.Table Global Secondary Hyperparathyroidism Drug Market Forecast (Million USD) Share by Demand 2021f-2026f

List of Figure

1.Figure Global Secondary Hyperparathyroidism Drug Market Size under the Impact of COVID-19, 2017-2021f (USD Million)

2.Figure Global Secondary Hyperparathyroidism Drug Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)

3.Figure Global Secondary Hyperparathyroidism Drug Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)

4.Figure Global Secondary Hyperparathyroidism Drug Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)

5.Figure Global Secondary Hyperparathyroidism Drug Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)

6.Figure Global Secondary Hyperparathyroidism Drug Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)

7.Figure Global Secondary Hyperparathyroidism Drug Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)

8.Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

9.Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

10.Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

11.Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

12.Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

13.Figure Evocalcet Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

14.Figure LNP-1892 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

15.Figure AJT-240 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

16.Figure Cinacalcet Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

17.Figure CTA-091 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

18.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

19.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

20.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

21.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

22.Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

23.Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

24.Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

25.Figure Evocalcet Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

26.Figure LNP-1892 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

27.Figure AJT-240 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

28.Figure Cinacalcet Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

29.Figure CTA-091 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

30.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

31.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

32.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

33.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

34.Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

35.Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

36.Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

37.Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

38.Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

39.Figure Evocalcet Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

40.Figure LNP-1892 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

41.Figure AJT-240 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

42.Figure Cinacalcet Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

43.Figure CTA-091 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

44.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

45.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

46.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

47.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

48.Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

49.Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

50.Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

51.Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

52.Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

53.Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

54.Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

55.Figure Evocalcet Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

56.Figure LNP-1892 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

57.Figure AJT-240 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

58.Figure Cinacalcet Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

59.Figure CTA-091 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

60.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

61.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

62.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

63.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

64.Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

65.Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

66.Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

67.Figure Evocalcet Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

68.Figure LNP-1892 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

69.Figure AJT-240 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

70.Figure Cinacalcet Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

71.Figure CTA-091 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

72.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

73.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

74.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

75.Figure O

Summary

Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.

The global Secondary Hyperparathyroidism Drug market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Secondary Hyperparathyroidism Drug market segmented into
Evocalcet
LNP-1892
AJT-240
Cinacalcet Hydrochloride
CTA-091
Others

Based on the end-use, the global Secondary Hyperparathyroidism Drug market classified into
Hospital
Clinic
Others

Based on geography, the global Secondary Hyperparathyroidism Drug market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are
Deltanoid Pharmaceuticals Inc
EA Pharma Co Ltd
Lupin Ltd
Mitsubishi Tanabe Pharma Corp
OPKO Health Inc
Shire Plc